Please assess the completion status of the following clinical trial:

Trial Title: A Study in Sepsis Patients With Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the age of 18 and 80 years.~* Proven or suspected infection.~* Two out of four SIRS criteria of systemic inflammation, existing for less than 24 hours after admission in the intensive care unit, as follows:~  * Core temperature higher then 38 degree Celsius or lower then 36 degree Celsius.~ * Heart rate above 90 beats/min (unless the patient has a medical condition known to increase heart rate or is receiving treatment that would prevent tachycardia).~ * Respiratory rate above 20 breaths/min, a PaCO2 lower then 32mmHg or the use of mechanical ventilation for an acute respiratory process.~ * White-cell count above 12,000/mm3 or below 4,000/mm3 or a differential count showing \>10 percent immature neutrophils.~* Acute renal failure, defined as~  * Rise in serum creatinine level to ≥150μmol/L within the previous 48 hours, in the absence of primary underlying renal disease OR~ * Minimally a stage 1 Kidney Injury according to AKIN creatinine criteria: Increase in serum creatinine ≥26.2µmol/L (0.3mg/dL) or increase to ≥150% (≥1.5 -fold) from baseline in the previous 48 hours in the absence of primary underlying renal disease and where baseline creatinine is less than 150 µmol/L) OR~ * Minimally a stage 1 Kidney Injury according to AKIN Urine Output criteria: Urine Output of ≤ 0.5mg/kg/h for ≥6h and following adequate fluid resuscitation when applicable, in the absence of underlying primary renal disease and where baseline creatinine is less than 150µmol/L)~* Written informed consent obtained prior to any study intervention.~Exclusion Criteria:~* Pregnant women or nursing mothers and fecund females who are not on effective contraception (chemical: pill; or mechanical: IUD)~* Patients already on dialysis (RTT) at entry~* Known HIV (sero-positive) patients~* Patients receiving immunosuppressant therapy or on chronic high doses of steroids equivalent to prednisone 1mg/Kg/day~* Patients expected to have rapidly fatal disease within 24 hours~* Known confirmed gram-positive sepsis~* Known confirmed fungal sepsis~* Acute pancreatitis with no established source of infection~* Patients not expected to survive for 28 days due to other medical conditions such as end-stage neoplasm or other diseases~* Participation in another investigational study within 90 days prior to start of the study which might interfere with this study~* Any previous administration of active study medication.~* Known allergy for dairy (bovine) products including cow milk.~* Sepsis without renal failure as defined in the Entry Criteria.~* History of chronic renal failure or history of persistent creatinine level equal or greater than 150umol/L prior to entry for reasons other than the current sepsis condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bovine Intestinal AP (Type: EXPERIMENTAL): Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)
- 2 (Type: PLACEBO_COMPARATOR): Placebo Intravenous administration of 10 bolus and 48h continuous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).